search
Back to results

Anemia Correction and Fibroblast Growth Factor 23 Levels in Chronic Kidney Disease , and Renal Transplant Patient

Primary Purpose

Anemia of Chronic Kidney Disease, Endothelial Dysfunction, Left Ventricular Hypertrophy

Status
Suspended
Phase
Not Applicable
Locations
Egypt
Study Type
Interventional
Intervention
detailed echocardiography
serum fibroblast growth factor-23
flow mediated dilatation of forearm
Sponsored by
Omnia Mohammed Hashem
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Anemia of Chronic Kidney Disease

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

All patients:

  1. Above 18 years old
  2. Diagnosed as CKD, and renal transplanted patients at Assiut University Hospital in the period 2017-2020 .

Exclusion Criteria:

  1. Severely hypocalcaemic patients < 7mg/dl.
  2. Severely hyperphosphatemic patients >7 mg/dl .
  3. Uncontrolled hypertensive patients ( more than 3 antihypertensive drugs).
  4. Uncontrolled diabetic patients HBA1C >8 .
  5. Blood transfusion dependent

Sites / Locations

  • Assiut University Hospitals

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

CKD patients with different stages

Newly renal transplanted patients .

Arm Description

Full clinical history and through clinical examination. Full blood count at time of diagnosis and 3 months after initiation of treatment with iron and erythropoietin Stimulating agents. Iron study at time of diagnosis and 3 months after treatment . Serum calcium , phosphorus, intact Parathrmone hormone. 5-24- urinary proteins or Albumin Creatinine ratio every month (for 3 months )then every 3 months (1 st year), then annually. 6- Lipid profile . 7-Estimated glomerular filtration rate by MDRD equation .

Full clinical history and through clinical examination. Pre transplant Serum calcium , phosphorus , I Parathrmone hormone , serial measures every / 3 months for 2 years. Pre-transplant full blood count serial measures every / 3 months for 2 years. Pre transplant serum Iron study and annually for 2 years. 24- urinary proteins or albumin-creatinine ratio every month (for 3 months )then every 3 months (1 st year), then annually. Post-transplant serum FGF-23 (as independent risk factor) at 6months. Different immunosuppressive protocols. Pre-transplant panel reactive antibody,donor-specific antibody

Outcomes

Primary Outcome Measures

if change of in Hemoglobin level and correction of anemia associated with change in the left ventricular outcomes
measure the left ventricular mass index (gm/m2)
the relationship between the FGF-23 and degree of left ventricular dysfunction
measure FGF-23 level in (pg/ml)
the relationship between FGF-23 level and early endothelial dysfunction
change in arterial diameter in mm

Secondary Outcome Measures

Full Information

First Posted
May 26, 2017
Last Updated
June 25, 2018
Sponsor
Omnia Mohammed Hashem
search

1. Study Identification

Unique Protocol Identification Number
NCT03193073
Brief Title
Anemia Correction and Fibroblast Growth Factor 23 Levels in Chronic Kidney Disease , and Renal Transplant Patient
Official Title
Impact of Anemia Correction and Fibroblast Growth Factor 23 Levels in Left Ventricular Hypertrophy, and Early Endothelial Dysfunction in Chronic Kidney Disease, and Renal Transplant Patient
Study Type
Interventional

2. Study Status

Record Verification Date
June 2018
Overall Recruitment Status
Suspended
Why Stopped
problem in funding which will be solved by the end of August
Study Start Date
September 1, 2018 (Anticipated)
Primary Completion Date
September 1, 2020 (Anticipated)
Study Completion Date
December 1, 2020 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Omnia Mohammed Hashem

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The fibroblast growth factor-23-bone-kidney axis is part of newly discovered biological systems linking bone to other organ functions through a complex endocrine network that is integrated with the parathormone/vitamin D axis and which plays an equally important role in health and disease . Most of the known physiological function of fibroblast growth factor 23 to regulate mineral metabolism can be accounted for by actions of this hormone on the kidney.In a recent experimental study, fibroblast growth factor-23 was shown to cause pathological hypertrophy in rat cardiomyocytes by "calcineurin-nuclear factor of activated T cells" and treatment with fibroblast growth factor -blockers reduced left ventricular hypertrophy in experimental models of chronic renal failure.The current hypothesis is that, in healthy individuals, iron deficiency stimulates increased production of fibroblast growth factor23. At the same time, iron is thought to be the cofactor of enzymes taking part in the degradation of intact fibroblast growth factor-23 and thought to have a role in the excretion of degraded FGF-23 parts .Studies speculated that Angiotensin Converting Enzyme inhibitors may exert their anti-proteinuria effects at least in part by reducing serum fibroblast growth factor-23 levels although it is difficult from the results of this study to understand which comes first and brings about the other; decrease in proteinuria or fibroblast growth factor-23. Available evidence points to the deleterious effects of increased fibroblast growth factor-23 level in proteinuria, but the precise molecular mechanism still remains to be explored. An intricate and close association exists among parathormone, phosphorus, active vitamin D with FGF23, but the independent role of the latter on proteinuria is the least explored. Elaborately conducted studies that control effects of confounding factors adequately are needed to demonstrate the independent pathogenic role of FGF23.
Detailed Description
To study the effect of anemia correction and left ventricular hypertrophy in Chronic Kidney Disease patients and renal transplant patients . To study the relation of fibroblast growth factor and Left ventricular hypertrophy in Chronic kidney disease and renal transplant patients. To study the relation between fibroblast growth factor 23 and early endothelial dysfunction in both Chronic kidney disease and renal transplant patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Anemia of Chronic Kidney Disease, Endothelial Dysfunction, Left Ventricular Hypertrophy, Fibroblast Growth Factor 23

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
two groups of patients (group A: CKD and group B newly transplanted patients) are assigned for detailed echocardiography , serum FGF-23, flow mediated dilatation of the forearm before anaemia correction in group A and renal transplant in group B . Also assesment of FGF-23 in different stages of group A, assessment of FGF-23 before and after renal transplant
Masking
None (Open Label)
Allocation
Randomized
Enrollment
80 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
CKD patients with different stages
Arm Type
Active Comparator
Arm Description
Full clinical history and through clinical examination. Full blood count at time of diagnosis and 3 months after initiation of treatment with iron and erythropoietin Stimulating agents. Iron study at time of diagnosis and 3 months after treatment . Serum calcium , phosphorus, intact Parathrmone hormone. 5-24- urinary proteins or Albumin Creatinine ratio every month (for 3 months )then every 3 months (1 st year), then annually. 6- Lipid profile . 7-Estimated glomerular filtration rate by MDRD equation .
Arm Title
Newly renal transplanted patients .
Arm Type
Active Comparator
Arm Description
Full clinical history and through clinical examination. Pre transplant Serum calcium , phosphorus , I Parathrmone hormone , serial measures every / 3 months for 2 years. Pre-transplant full blood count serial measures every / 3 months for 2 years. Pre transplant serum Iron study and annually for 2 years. 24- urinary proteins or albumin-creatinine ratio every month (for 3 months )then every 3 months (1 st year), then annually. Post-transplant serum FGF-23 (as independent risk factor) at 6months. Different immunosuppressive protocols. Pre-transplant panel reactive antibody,donor-specific antibody
Intervention Type
Diagnostic Test
Intervention Name(s)
detailed echocardiography
Intervention Description
Detailed Echocardiography including ejection fraction, interventricular septum thickness, posterior wall thickness, left ventricular end -diastolic and end- systolic diameter and left ventricular mass index will be correlated with body surface area for both groups serum FGF-23
Intervention Type
Diagnostic Test
Intervention Name(s)
serum fibroblast growth factor-23
Intervention Description
serum levels of FGF-23
Intervention Type
Diagnostic Test
Intervention Name(s)
flow mediated dilatation of forearm
Intervention Description
superficial sonar assess the diameter of brachial vessel on exposure to stress
Primary Outcome Measure Information:
Title
if change of in Hemoglobin level and correction of anemia associated with change in the left ventricular outcomes
Description
measure the left ventricular mass index (gm/m2)
Time Frame
measures at time of diagnosis then after 3 months
Title
the relationship between the FGF-23 and degree of left ventricular dysfunction
Description
measure FGF-23 level in (pg/ml)
Time Frame
measure at time of diagnosis
Title
the relationship between FGF-23 level and early endothelial dysfunction
Description
change in arterial diameter in mm
Time Frame
at time of diagnosis in chronic kidney disease / after 6 months in renal transplant

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: All patients: Above 18 years old Diagnosed as CKD, and renal transplanted patients at Assiut University Hospital in the period 2017-2020 . Exclusion Criteria: Severely hypocalcaemic patients < 7mg/dl. Severely hyperphosphatemic patients >7 mg/dl . Uncontrolled hypertensive patients ( more than 3 antihypertensive drugs). Uncontrolled diabetic patients HBA1C >8 . Blood transfusion dependent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mohammed Ali Tohamy, professor
Organizational Affiliation
Assiut University
Official's Role
Study Director
Facility Information:
Facility Name
Assiut University Hospitals
City
Assiut
Country
Egypt

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
26437603
Citation
Grabner A, Amaral AP, Schramm K, Singh S, Sloan A, Yanucil C, Li J, Shehadeh LA, Hare JM, David V, Martin A, Fornoni A, Di Marco GS, Kentrup D, Reuter S, Mayer AB, Pavenstadt H, Stypmann J, Kuhn C, Hille S, Frey N, Leifheit-Nestler M, Richter B, Haffner D, Abraham R, Bange J, Sperl B, Ullrich A, Brand M, Wolf M, Faul C. Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy. Cell Metab. 2015 Dec 1;22(6):1020-32. doi: 10.1016/j.cmet.2015.09.002. Epub 2015 Oct 1.
Results Reference
result
PubMed Identifier
26787561
Citation
Torun D, Yildiz I, Micozkadioglu H, Nursal GN, Yigit F, Ozelsancak R. The effects of cinacalcet treatment on bone mineral metabolism, anemia parameters, left ventricular mass index and parathyroid gland volume in hemodialysis patients with severe secondary hyperparathyroidism. Saudi J Kidney Dis Transpl. 2016 Jan;27(1):15-22. doi: 10.4103/1319-2442.174053.
Results Reference
result
PubMed Identifier
23505057
Citation
Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res. 2013 Aug;28(8):1793-803. doi: 10.1002/jbmr.1923.
Results Reference
result
PubMed Identifier
26394828
Citation
Eser B, Yayar O, Buyukbakkal M, Erdogan B, Ercan Z, Merhametsiz O, Haspulat A, Oguz EG, Dogan I, Canbakan B, Ayli MD. Fibroblast growth factor is associated to left ventricular mass index, anemia and low values of transferrin saturation. Nefrologia. 2015;35(5):465-72. doi: 10.1016/j.nefro.2015.06.025. Epub 2015 Sep 26. English, Spanish.
Results Reference
result
PubMed Identifier
26439537
Citation
Io H, Aizawa M, Funabiki K, Horikoshi S, Tomino Y. Impact of anaemia treatment for left ventricular remodelling prior to initiation of dialysis in chronic kidney disease patients: Efficacy and stability of long acting erythropoietin stimulating agents. Nephrology (Carlton). 2015 Dec;20 Suppl 4:7-13. doi: 10.1111/nep.12640.
Results Reference
result

Learn more about this trial

Anemia Correction and Fibroblast Growth Factor 23 Levels in Chronic Kidney Disease , and Renal Transplant Patient

We'll reach out to this number within 24 hrs